Last week, we looked at cresomycin, a new synthetic antibiotic developed by researchers at the University of Illinois Chicago and Harvard University. We asked for your opinions on how do you think synthetic antibiotics like cresomycin will impact the future of medicine. 💊 The results are in, 48% of you thought it was too early to tell, and 26% think it is useful, but not a game changer. This cautious approach is telling of our industry, where precaution is essential for steady growth. Leave your thoughts on these results in the comments! 💬 #iPharm #antibiotic #drugdevelopment
i-Pharm Consulting’s Post
More Relevant Posts
-
MPharm - Quality Assurance Student at Parul University | Pharmacist | Parul Institute of Pharmacy and Research '25
Attended an Invaluable Webinar session on " Bioanalysis : Scope and Challenges in Contemporary Approaches for New Drug Modalities". 🔬🧪 I would like to extend thanks to Aditya College of Pharmacy for organizing such Informative session providing Insights about recent scope and challenges.💊 #Bioanalysis #DrugDiscovery
To view or add a comment, sign in
-
-
#Biosimilars play a critical role in the European Healthcare System, generating savings for #payers, creating headroom for #innovation, and expanding #access to biologic therapy for patients. IQVIA’s ‘Impact of Biosimilar Competition in Europe 2023’ white paper reflects upon the effects on price, volume and market share following the arrival of biosimilar competition in Europe; the 9th iteration of this report provide 5 key observations on the current market. See our highlights below, or read the full paper here: https://lnkd.in/eehT6Mc2 Do you have a biosimilar product? Learn how Impact could support you at any stage of the development cycle on our website: https://lnkd.in/eEZXnzPW
To view or add a comment, sign in
-
IQVIA’s latest white paper sheds light on the ongoing challenges to #biosimilar access and adoption in Europe. Highlighted within the report, and in our summary below, is the growing disparity in biosimilar #access among European countries, the plateauing of biosimilar savings, and the limited pipeline that exists for certain #biologic medicines. Together, these findings signal a need for strategic intervention. Effective medical communication plays a pivotal role in addressing these challenges by increasing awareness and understanding among key stakeholders. Through tailored education programs, physicians gain insights into the efficacy and benefits of biosimilars, payers learn to navigate cost-saving opportunities more effectively, and policymakers are equipped to implement supportive policies that facilitate greater biosimilar adoption. Drawing from IQVIA’s observations, it is clear future savings from biosimilars in Europe are not guaranteed and will depend on continued awareness efforts to maximize their impact and sustainability. Do you have a biosimilar product? Learn how Impact could support you at any stage of the development cycle on our website: https://lnkd.in/eEZXnzPW #medcomms #meded #medicaleducation
#Biosimilars play a critical role in the European Healthcare System, generating savings for #payers, creating headroom for #innovation, and expanding #access to biologic therapy for patients. IQVIA’s ‘Impact of Biosimilar Competition in Europe 2023’ white paper reflects upon the effects on price, volume and market share following the arrival of biosimilar competition in Europe; the 9th iteration of this report provide 5 key observations on the current market. See our highlights below, or read the full paper here: https://lnkd.in/eehT6Mc2 Do you have a biosimilar product? Learn how Impact could support you at any stage of the development cycle on our website: https://lnkd.in/eEZXnzPW
To view or add a comment, sign in
-
Functional personalized medicine is an interesting approach aiming at identifying unexpected therapeutic options for each patient. Patient-derived organoids appear as a promising and scalable technology to enable ex vivo drug tests and implement them in the clinics Read More: https://lnkd.in/eAYZd2fc #cellculture #researcher #kosheeka #biotechnology #primarycells
To view or add a comment, sign in
-
-
Building a successful company in the biotech industry requires more than an innovative product that fills an unmet need in the market. It also requires dynamic leadership and an unyielding commitment to success. As the CEO of CytoAgents, Teresa Whalen, RPh leads a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of groundbreaking treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. Learn more about Teresa and the CytoAgents team here: https://lnkd.in/g7P29x3i #biotech #biotechleadership #biotechnology #cytokinereleasesyndrome #crs
To view or add a comment, sign in
-
-
The discovery of #penicillin was one of the greatest inventions of the twentieth century. Unfortunately, less than a hundred years later, we find ourselves back where we started due to the rise of #antibioticresistance that leaves us without effective treatments for bacterial infections. How do we navigate this new challenge? From #phagetherapy and #naturalproducts discovery to #AI-aided drug design and #microbiome-based therapies, here are some #biotechnology solutions for the growing antibiotics crisis. Read to learn more: https://lnkd.in/eps8bfbx
To view or add a comment, sign in
-
-
Interesting clip (and a link to a full length webinar) on #MedPharm's 3D nasal cast model! #nasaldelivery #nasalformulationdevelopment
MedCast is a 3D-printed model of the human nasal cavity designed to help refine and optimize nasal formulations. Its unique technology allows us to assess the suitability of a formulation for nasal delivery, and the ability of the drug-device combo to deliver the drug to the targeted regions. In their respiratory models webinar, MedPharm's Research Biology & Innovation experts Jon Volmer and Aisley Amegashie discuss how MedCast was designed and is being used to support nasal drug development programs. Visit our website for more information: https://lnkd.in/eM9fw_eC #innovation #technology #nasaldelivery #respiratory
To view or add a comment, sign in
-
🌿Unlocking Nature's Secrets: Bioprospecting for Life-Changing Medicines🌿 Did you know that some of the most powerful medicines come from the natural world? Bioprospecting is the process of discovering and harnessing the medicinal properties of plants, and our latest video takes you on a fascinating journey to explore this incredible field. Meet Taxol, a potent anticancer agent extracted from the flowers of the Pacific yew tree, which resemble cherries. This remarkable compound has transformed cancer treatment, offering new hope to patients worldwide. Watch our video to learn more about the incredible world of bioprospecting. Discover our page: https://lnkd.in/eNHDsTvf #Bioprospecting #Taxol #CancerResearch #Medicine #MedicalAnimation #ScientificCommunication #3Danimation #Pharma #Science #Healthcare #ScientificAnimation #Biotech
To view or add a comment, sign in
-
⏰ Expressions of Interest are due tomorrow! Submit Expressions of Interest for new #preventatives, #diagnostics, and #therapeutics for drug-resistant bacteria before tomorrow, Mar. 29 at 23:59 ET to be considered in the first of two application cycles. 🔗 Apply: bit.ly/3P56UDB #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology #LMICs #antibiotics
To view or add a comment, sign in
-
-
Recent #clinicaltrials have proven successful for #novel drug #Remofuscin... In the article, "Remofuscin slows retinal thinning in Stargardt Disease (STGD1)—results from the Stargardt Remofuscin Treatment Trial (STARTT), a 2-year placebo-controlled study," the authors describe a successful clinical trial of a novel drug, Remofuscin, recently tested in humans for the removal of an aging product, lipofuscin, accumulating in the retinal epithelium layer (RPE), a layer of cells feeding the retinal cells proper. What is remarkable is that lipofuscin, the product of membrane oxidation and metal complexation that until recently was deemed inexorably accumulating in an aging body, can be cleared in 3–4 days by an oxidation process induced by the drug. It seems like many functions of our organism are in a “grey zone” of reversibility; we just need effort and optimism that a breakthrough is possible. This is why we are so inspired to serve the #biotechnology field, the field defining progress, touching everybody’s existence, producing new cures, and fighting needless suffering. Below is the #chemical structure of the remarkable drug, which is so simple yet potent. Read the full article here: https://lnkd.in/d9PaJsPP #iplaw #patentlaw #biotech
To view or add a comment, sign in
-
More from this author
-
The Critical Role of Monitoring and Data Quality in Early-Stage Clinical Trials
i-Pharm Consulting 1mo -
The Rise of Trial Site Networks in Australia: A New Frontier in Clinical Research
i-Pharm Consulting 2mo -
Ventilator Recalls: A Catalyst for Quality Improvement in Medical Devices
i-Pharm Consulting 3mo